Will Amylyx’s ALS Drug Benefit From US FDA’s Aduhelm Experience?

05 Jul 2022

A rare second advisory committee meeting is scheduled for Amylyx’s ALS drug to discuss additional analyses that the company submitted, allowing another glimpse into the FDA’s pre-decision thinking.

Astrocyte and blood vessel — The second advisory committee meeting will offer another opportunity for the public to learn about FDA's thinking on AMX0035. • Source: Shutterstock

Will Amylyx’s ALS Drug Benefit From US FDA’s Aduhelm Experience?

More from US FDA Performance Tracker

More from Regulatory Trackers